Evaluating the Potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A Pilot Study

• Published in: Nutrients Vol. 15; no. 19; p. 4174
• Main Authors: Qu, Yunyao, Park, Si Hong, Dallas, David C
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 27-09-2023; MDPI
• Subjects: Antibiotics; bovine kappa-casein glycomacropeptide (GMP); Casein; Clinical trials; dairy-derived peptide; Feces; Gastrointestinal diseases; Gastrointestinal surgery; gut microbiota; Inflammation; Intervention; intestinal immune markers; Irritable bowel syndrome; irritable bowel syndrome (IBS); low-grade inflammation; Medical research; Medicine, Experimental; Microbiota; Microbiota (Symbiotic organisms); Motility; Prebiotics; Probiotics; Proteins; Questionnaires
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu15194174

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects 10–15% of the global population and presents symptoms such as abdominal discomfort, bloating and altered bowel habits. IBS is believed to be influenced by gut microbiota alterations and low-grade inflammation. Bovine kappa-casein glycomacropeptide (GMP), a bioactive dairy-derived peptide, possesses anti-adhesive, prebiotic and immunomodulatory properties that could potentially benefit IBS patients. This pilot study investigated the effects of daily supplementation with 30 g of GMP for three weeks on gut health in five people with IBS. We assessed alterations in gut microbiota composition, fecal and blood inflammatory makers, and gut-related symptoms before, during and after the GMP feeding period. The results revealed no changes in fecal microbiota, subtle effects on systemic and intestinal immune makers, and no changes in gut-related symptoms during and after the GMP supplementation. Further research is needed to assess the potential benefits of GMP in IBS patients, including the examination of dosage and form of GMP supplementation.